Plasma neurofilament light chain concentrations are elevated in youth-onset type 2 diabetes and associated with neuropathy

IF 3.9 3区医学 Q1 CLINICAL NEUROLOGY

Journal of the Peripheral Nervous System Pub Date : 2023-06-21 DOI:10.1111/jns.12575

Vera Fridman, Stefan Sillau, Alanna Ritchie, Jacob Bockhorst, Christina Coughlan, Paula Araya, Joaquin M. Espinosa, Keith Smith, Ethan M. Lange, Leslie A. Lange, Laure El Ghormli, Kimberly L. Drews, Philip Zeitler, Jane E. B. Reusch

{"title":"Plasma neurofilament light chain concentrations are elevated in youth-onset type 2 diabetes and associated with neuropathy","authors":"Vera Fridman, Stefan Sillau, Alanna Ritchie, Jacob Bockhorst, Christina Coughlan, Paula Araya, Joaquin M. Espinosa, Keith Smith, Ethan M. Lange, Leslie A. Lange, Laure El Ghormli, Kimberly L. Drews, Philip Zeitler, Jane E. B. Reusch","doi":"10.1111/jns.12575","DOIUrl":null,"url":null,"abstract":"<div>\n \n \n <section>\n \n <h3> Background and Aims</h3>\n \n <p>The lack of easily measurable biomarkers remains a challenge in executing clinical trials for diabetic neuropathy (DN). Plasma Neurofilament light chain (NFL) concentration is a promising biomarker in immune-mediated neuropathies. Longitudinal studies evaluating NFL in DN have not been performed.</p>\n </section>\n \n <section>\n \n <h3> Methods</h3>\n \n <p>A nested case–control study was performed on participants with youth-onset type 2 diabetes enrolled in the prospective Treatment Options for Type 2 Diabetes in Adolescents and Youth (TODAY) study. Plasma NFL concentrations were measured at 4-year intervals from 2008 to 2020 in 50 participants who developed DN and 50 participants with type 2 diabetes who did not develop DN.</p>\n </section>\n \n <section>\n \n <h3> Results</h3>\n \n <p>NFL concentrations were similar in the DN and no DN groups at the first assessment. Concentrations were higher in DN participants at all subsequent assessment periods (all <i>p</i> < .01). NFL concentrations increased over time in both groups, with higher degrees of change in DN participants (interaction <i>p</i> = .045). A doubling of the NFL value at Assessment 2 in those without DN increased the odds of ultimate DN outcome by an estimated ratio of 2.86 (95% CI: [1.30, 6.33], <i>p</i> = .0046). At the final study visit, positive Spearman correlations (controlled for age, sex, diabetes duration, and BMI) were observed between NFL and HbA1c (0.48, <i>p</i> < .0001), total cholesterol (0.25, <i>p</i> = .018), and low-density lipoprotein (LDL (0.30, <i>p</i> = .0037)). Negative correlations were observed with measures of heart rate variability (−0.42 to −0.46, <i>p</i> = <.0001).</p>\n </section>\n \n <section>\n \n <h3> Interpretation</h3>\n \n <p>The findings that NFL concentrations are elevated in individuals with youth-onset type 2 diabetes, and increase more rapidly in those who develop DN, suggest that NFL could be a valuable biomarker for DN.</p>\n </section>\n </div>","PeriodicalId":17451,"journal":{"name":"Journal of the Peripheral Nervous System","volume":null,"pages":null},"PeriodicalIF":3.9000,"publicationDate":"2023-06-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1111/jns.12575","citationCount":"1","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of the Peripheral Nervous System","FirstCategoryId":"3","ListUrlMain":"https://onlinelibrary.wiley.com/doi/10.1111/jns.12575","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"CLINICAL NEUROLOGY","Score":null,"Total":0}

引用次数: 1

Abstract

Background and Aims

The lack of easily measurable biomarkers remains a challenge in executing clinical trials for diabetic neuropathy (DN). Plasma Neurofilament light chain (NFL) concentration is a promising biomarker in immune-mediated neuropathies. Longitudinal studies evaluating NFL in DN have not been performed.

Methods

A nested case–control study was performed on participants with youth-onset type 2 diabetes enrolled in the prospective Treatment Options for Type 2 Diabetes in Adolescents and Youth (TODAY) study. Plasma NFL concentrations were measured at 4-year intervals from 2008 to 2020 in 50 participants who developed DN and 50 participants with type 2 diabetes who did not develop DN.

Results

NFL concentrations were similar in the DN and no DN groups at the first assessment. Concentrations were higher in DN participants at all subsequent assessment periods (all p < .01). NFL concentrations increased over time in both groups, with higher degrees of change in DN participants (interaction p = .045). A doubling of the NFL value at Assessment 2 in those without DN increased the odds of ultimate DN outcome by an estimated ratio of 2.86 (95% CI: [1.30, 6.33], p = .0046). At the final study visit, positive Spearman correlations (controlled for age, sex, diabetes duration, and BMI) were observed between NFL and HbA1c (0.48, p < .0001), total cholesterol (0.25, p = .018), and low-density lipoprotein (LDL (0.30, p = .0037)). Negative correlations were observed with measures of heart rate variability (−0.42 to −0.46, p = <.0001).

Interpretation

The findings that NFL concentrations are elevated in individuals with youth-onset type 2 diabetes, and increase more rapidly in those who develop DN, suggest that NFL could be a valuable biomarker for DN.

查看原文本刊更多论文

青年期2型糖尿病患者血浆神经丝轻链浓度升高，并与神经病变相关。

背景和目的：在糖尿病神经病变（DN）的临床试验中，缺乏易于测量的生物标志物仍然是一个挑战。血浆神经丝轻链（NFL）浓度是免疫介导的神经病变中一种很有前途的生物标志物。尚未进行评估DN中NFL的纵向研究。方法：对参与青少年2型糖尿病前瞻性治疗方案（TODAY）研究的青年发病2型糖尿病参与者进行嵌套病例对照研究。从2008年到2020年，每隔4年测量50名患DN的参与者和50名未患DN的2型糖尿病参与者的血浆NFL浓度。结果：在第一次评估时，DN组和无DN组的NFL浓度相似。DN参与者在随后的所有评估期内的浓度都较高（所有p 解释：研究结果表明，青年期2型糖尿病患者的NFL浓度升高，而DN患者的NFL浓度增加更快，这表明NFL可能是DN的一个有价值的生物标志物。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Journal of the Peripheral Nervous System 医学-临床神经学

CiteScore

6.10

自引率

7.90%

发文量

审稿时长

>12 weeks

期刊介绍： The Journal of the Peripheral Nervous System is the official journal of the Peripheral Nerve Society. Founded in 1996, it is the scientific journal of choice for clinicians, clinical scientists and basic neuroscientists interested in all aspects of biology and clinical research of peripheral nervous system disorders. The Journal of the Peripheral Nervous System is a peer-reviewed journal that publishes high quality articles on cell and molecular biology, genomics, neuropathic pain, clinical research, trials, and unique case reports on inherited and acquired peripheral neuropathies. Original articles are organized according to the topic in one of four specific areas: Mechanisms of Disease, Genetics, Clinical Research, and Clinical Trials. The journal also publishes regular review papers on hot topics and Special Issues on basic, clinical, or assembled research in the field of peripheral nervous system disorders. Authors interested in contributing a review-type article or a Special Issue should contact the Editorial Office to discuss the scope of the proposed article with the Editor-in-Chief.